SC
BEAM icon

Scholtz & Company’s Beam Therapeutics BEAM Stock Holding History

Scholtz & Company’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,875
Closed -$250K – 62
2021
Q3 		$250K Sell
2,875
-70
-2% -$7.03K 0.09% 61
2021
Q2 		$379K Buy
+2,945
New +$235K 0.13% 62

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Scholtz & Company's BEAM Position: Q4 2021 in Review

Scholtz & Company sold out of Beam Therapeutics (BEAM) in Q4 2021, closing a stake of 2,875 shares — an estimated $250K sold.

Scholtz & Company first reported a position in BEAM in Q2 2021 and held it in 2 quarters. The position peaked at $379K in Q2 2021. 232 funds tracked by Wall St. Rank hold BEAM as of Q4 2021.

  • Scholtz & Company reported no remaining Beam Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Scholtz & Company sold 2,875 Beam Therapeutics shares in Q4 2021, an estimated $250K.
  • Scholtz & Company first reported a position in Beam Therapeutics in Q2 2021 and held it in 2 quarters.
  • Scholtz & Company's Beam Therapeutics position peaked at $379K in Q2 2021.
  • 232 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2021.

Based on Scholtz & Company's 13F filing for Q4 2021, filed 15 Feb 2022.